Testing immune cells engineered to fight a rare blood cancer

Plain-English translation of NCT04083495 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new treatment called ATLCAR.CD30, which uses your own immune cells that have been genetically engineered in a laboratory to recognize and attack your cancer. Researchers collect some of your blood cells, modify them to target cancer cells that carry a protein called CD30, and then give the modified cells back to you through an infusion. This approach is designed to help your immune system fight lymphoma that has come back or no longer responds to standard treatments.

Peripheral T-cell lymphoma is a rare blood cancer, and many patients whose cancer returns or stops responding to initial treatment have very few options left. This medication represents a newer approach that harnesses the power of your own immune system to target cancer cells, potentially offering hope to patients who have exhausted standard treatment options.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with CD30-positive peripheral T-cell lymphoma that has come back or stopped responding to prior treatments
you have received at least two previous lines of cancer therapy, or one line if your cancer came back very quickly or you were not eligible for certain standard treatments
you are in good enough health to tolerate this treatment (with a Karnofsky score above 60%)
if you are a woman of childbearing age, you are willing to use two forms of contraception for 6 months after treatment

You likely don't qualify if…

you have a positive pregnancy test or are not willing to use contraception during the trial
you have received an allogeneic stem cell transplant less than 180 days ago or are still on immunosuppressive medications
you have an active, serious infection or uncontrolled medical condition that would make participation unsafe
you are allergic to bendamustine or fludarabine, the chemotherapy drugs used to prepare your body for the cell infusion

What participation looks like

First, doctors will collect some of your blood cells, either through regular blood draws or a special procedure called leukapheresis. While your cells are being engineered in the laboratory (which takes several weeks), you may receive standard chemotherapy to help control your cancer. Once your modified cells are ready, you'll receive chemotherapy to prepare your body, followed by an infusion of your engineered cells through an IV. You'll return for a scan about 8 weeks later to see how well the treatment is working. If your cancer responds well and you meet other eligibility requirements, you may receive a second round of chemotherapy and a second infusion of cells.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Testing immune cells engineered to fight a rare blood cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)